Correlation Between FactSet Research and Bristol-Myers Squibb
Can any of the company-specific risk be diversified away by investing in both FactSet Research and Bristol-Myers Squibb at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining FactSet Research and Bristol-Myers Squibb into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between FactSet Research Systems and Bristol Myers Squibb, you can compare the effects of market volatilities on FactSet Research and Bristol-Myers Squibb and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in FactSet Research with a short position of Bristol-Myers Squibb. Check out your portfolio center. Please also check ongoing floating volatility patterns of FactSet Research and Bristol-Myers Squibb.
Diversification Opportunities for FactSet Research and Bristol-Myers Squibb
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between FactSet and Bristol-Myers is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding FactSet Research Systems and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and FactSet Research is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on FactSet Research Systems are associated (or correlated) with Bristol-Myers Squibb. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of FactSet Research i.e., FactSet Research and Bristol-Myers Squibb go up and down completely randomly.
Pair Corralation between FactSet Research and Bristol-Myers Squibb
Considering the 90-day investment horizon FactSet Research is expected to generate 1.82 times less return on investment than Bristol-Myers Squibb. But when comparing it to its historical volatility, FactSet Research Systems is 2.84 times less risky than Bristol-Myers Squibb. It trades about 0.19 of its potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest 80,055 in Bristol Myers Squibb on September 2, 2024 and sell it today you would earn a total of 20,500 from holding Bristol Myers Squibb or generate 25.61% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 98.44% |
| Values | Daily Returns |
FactSet Research Systems vs. Bristol Myers Squibb
Performance |
| Timeline |
| FactSet Research Systems |
| Bristol Myers Squibb |
FactSet Research and Bristol-Myers Squibb Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with FactSet Research and Bristol-Myers Squibb
The main advantage of trading using opposite FactSet Research and Bristol-Myers Squibb positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if FactSet Research position performs unexpectedly, Bristol-Myers Squibb can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will offset losses from the drop in Bristol-Myers Squibb's long position.| FactSet Research vs. Dun Bradstreet Holdings | FactSet Research vs. Moodys | FactSet Research vs. MSCI Inc | FactSet Research vs. Intercontinental Exchange |
| Bristol-Myers Squibb vs. Novartis AG | Bristol-Myers Squibb vs. Bayer AG | Bristol-Myers Squibb vs. Astellas Pharma | Bristol-Myers Squibb vs. Roche Holding AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Complementary Tools
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |